NCT07618364 The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease
| NCT ID | NCT07618364 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rinsada |
| Condition | Dry Eye Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 33 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 33 participants in total. It began in 2022-01-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The central hypothesis is that inflammation contributes to dry eye and that rinsing the palpebral conjunctiva, bulbar conjunctiva, and fornices will reduce the inflammatory burden on the ocular surface.
Eligibility Criteria
Inclusion Criteria: * MMP-9 Positivity in both eyes Exclusion Criteria: * Active ocular infection, including bacterial, viral, or fungal conjunctivitis Acute allergic conjunctivitis or severe seasonal ocular allergy flare History of autoimmune ocular surface disease (e.g., Sjögren syndrome, ocular cicatricial pemphigoid, Stevens-Johnson syndrome) Current use of topical anti-inflammatory medications, including corticosteroids, cyclosporine, lifitegrast, or topical NSAIDs within 14-30 days prior to enrollment Initiation of new ocular or systemic anti-inflammatory therapy during the study period Contact lens wear within 12-24 hours prior to testing Ocular surgery or laser procedures within the previous 3-6 months Current punctal plug use or punctal occlusion procedures within the prior 3 months Severe aqueous-deficient dry eye preventing adequate tear sample acquisition or reliable InflammaDry testing Use of preserved artificial tears within a specified washout period Eyelid abnormalities or active blepharitis requiring treatment Pregnancy or breastfeeding (optional depending on IRB requirements) History of hypersensitivity to saline irrigation or study materials Any systemic inflammatory disease judged by investigators to confound tear film MMP-9 level
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07618364 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dry Eye Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07618364 currently recruiting?
Yes, NCT07618364 is actively recruiting participants. Contact the research team at srini@rinsada.com for enrollment information.
Where is the NCT07618364 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07618364 clinical trial?
NCT07618364 is sponsored by Rinsada. The trial plans to enroll 33 participants.